{
  "abstract": "PIGA-CDG is a congenital disorder of glycosylation caused by pathogenic partial loss-of-function variants in the PIGA gene. PIGA encodes an enzyme responsible for the catalytic transfer of N-acetylglucosamine to phosphatidylinositol during the first step of glycosylphosphatidylinositol anchor biosynthesis. Loss of this enzyme has a widespread phenotypic impact, but primarily results in neurological symptoms including seizures, intellectual disability, and developmental delay. Currently, treatments are limited and focus on symptom management. We developed an eye model of PIGA-CDG that has a reduced eye size. We screened a library of 98% 1,520 FDA/EMA-approved compounds to find drugs that improved the small eye phenotype. This screen revealed numerous drugs that improved eye size, including those that targeted dopamine signaling and cyclooxygenases. Using pharmacological and genetic approaches, we show that modulating dopamine signaling improves the eye size. Genetic inhibition of dopamine 2 receptor signaling and dopamine reuptake improve both the eye model and neurologically relevant PIGA-CDG phenotypes, including seizures and locomotor deficits. We also pharmacologically and genetically validate cyclooxygenase targeting drugs in the eye model. These findings reveal novel biology underlying PIGA-CDG and point towards candidate therapeutic approaches. Author summary: PIGA-CDG is a rare neurodevelopmental disorder caused by pathogenic variants in the gene PIGA. Patients primarily display neurological symptoms, including seizures, developmental delay, and intellectual disability. Fewer than 100 patients have been identified, and treatment strategies are limited. In the context of rare diseases, de novo drug development is difficult due to the high cost, lengthy development times, and often too small of a patient population to conduct a clinical trial. Our lab leverages drug repurposing screening to circumvent many of the hurdles associated with de novo drug development. Here, we develop and screen FDA- or EMA-approved compounds on a Drosophila model of PIGA-CDG, uncovering novel biology underlying PIGA-associated pathophysiology. We use pharmacological and genetic tools to demonstrate that modifying dopamine signaling and abundance, as well as cyclooxygenase-mediated pathways, contribute to PIGA-associated phenotypes. This work highlights promising therapeutic targets for PIGA-CDG.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, Utah, United States of America"
  ],
  "article_type": "Research Article",
  "arxiv": null,
  "author_total": 3,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Miriam C. Aziz"
    },
    {
      "name": "Jennie Wilson"
    },
    {
      "name": "Clement Y. Chow"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/64j5zhkmte40z.bib",
  "cited_by": 0,
  "doi": "10.1371/journal.pgen.1012294",
  "fulltext_url": "https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1012294",
  "id": "64j5zhkmte40z",
  "issns": [
    "1553-7404"
  ],
  "landing_url": "https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1012294",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2737|Lysosomal Storage Disorders Research"
    ],
    [
      "plos",
      "/Biology and life sciences/Anatomy/Head/Eyes"
    ],
    [
      "plos",
      "/Biology and life sciences/Anatomy/Ocular system/Eyes"
    ],
    [
      "plos",
      "/Biology and life sciences/Biochemistry/Hormones/Catecholamines/Dopamine"
    ],
    [
      "plos",
      "/Biology and life sciences/Biochemistry/Neurochemistry/Neurochemicals/Levodopa"
    ],
    [
      "plos",
      "/Biology and life sciences/Biochemistry/Neurochemistry/Neurotransmitters/Biogenic amines/Catecholamines/Dopamine"
    ],
    [
      "plos",
      "/Biology and life sciences/Cell biology/Signal transduction/Cell signaling/Neurological signaling"
    ],
    [
      "plos",
      "/Biology and life sciences/Genetics/Heredity/Heterozygosity"
    ],
    [
      "plos",
      "/Biology and life sciences/Neuroscience/Neurochemistry/Neurochemicals/Levodopa"
    ],
    [
      "plos",
      "/Biology and life sciences/Neuroscience/Neurochemistry/Neurotransmitters/Biogenic amines/Catecholamines/Dopamine"
    ],
    [
      "plos",
      "/Biology and life sciences/Organisms/Eukaryota/Animals/Invertebrates/Arthropoda/Insects/Drosophila/Drosophila melanogaster"
    ],
    [
      "plos",
      "/Biology and life sciences/Physiology/Biological locomotion/Climbing"
    ],
    [
      "plos",
      "/Biology and life sciences/Zoology/Animals/Invertebrates/Arthropoda/Insects/Drosophila/Drosophila melanogaster"
    ],
    [
      "plos",
      "/Biology and life sciences/Zoology/Entomology/Insects/Drosophila/Drosophila melanogaster"
    ],
    [
      "plos",
      "/Medicine and health sciences/Anatomy/Head/Eyes"
    ],
    [
      "plos",
      "/Medicine and health sciences/Anatomy/Ocular system/Eyes"
    ],
    [
      "plos",
      "/Medicine and health sciences/Pharmacology/Drug screening"
    ],
    [
      "plos",
      "/Medicine and health sciences/Pharmacology/Drugs/Levodopa"
    ],
    [
      "plos",
      "/Physical sciences/Chemistry/Chemical compounds/Organic compounds/Amines/Catecholamines/Dopamine"
    ],
    [
      "plos",
      "/Physical sciences/Chemistry/Organic chemistry/Organic compounds/Amines/Catecholamines/Dopamine"
    ],
    [
      "plos",
      "/Research and analysis methods/Animal studies/Experimental organism systems/Animal models/Drosophila melanogaster"
    ],
    [
      "plos",
      "/Research and analysis methods/Animal studies/Experimental organism systems/Model organisms/Drosophila melanogaster"
    ],
    [
      "plos",
      "/Research and analysis methods/Model organisms/Drosophila melanogaster"
    ]
  ],
  "openalex": "W7154895225",
  "pdf_url": "https://journals.plos.org/plosgenetics/article/file?id=10.1371/journal.pgen.1012294&type=printable",
  "pmcid": null,
  "pmid": null,
  "published": "2026-08-31",
  "publisher": "Public Library of Science",
  "ris": "https://research.draconitic.com/paper/64j5zhkmte40z.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:18:02Z",
      "native_id": "10.1371/journal.pgen.1012294",
      "source": "plos",
      "url": "https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1012294"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "plos:anatomy",
      "subfield": "physiology"
    }
  ],
  "title": "A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG",
  "title_text": "A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:18:02Z",
  "url": "https://research.draconitic.com/paper/64j5zhkmte40z",
  "venue": "PLOS Genetics",
  "versions": []
}